Alex Lovejoy,
Principal Scientist
Alex Lovejoy earned his PhD in Biochemistry from Stanford University where he focused on developing new NGS-based technologies in Pat Brown’s lab. As a postdoctoral scholar in the Oncology Department at Stanford, he worked on the CAPP-Seq technology for ctDNA NGS, a technology which was acquired by Roche. For the past 3 years, he has been working in the Oncology Assay Development team at Roche Sequencing Solutions, improving upon the technology and designing and developing the next generation of oncology assays.
|
|
|
